VTV THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.5 USD | +2.10% |
|
+5.59% | +121.74% |
| Mar. 14 | VTv Therapeutics Inc. Announces Board Changes | CI |
| Mar. 13 | VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 2.02M | Sales 2023 | - | Capitalization | 23.43M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 | -20M | EV / Sales 2022 | 21.1 x |
| Net cash position 2022 | 11.42M | Net cash position 2023 | 8.98M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.59
x | P/E ratio 2023 |
-1.18
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.10% | ||
| 1 week | +5.59% | ||
| Current month | +8.37% | ||
| 1 month | +20.11% | ||
| 3 months | +196.86% | ||
| 6 months | +46.55% | ||
| Current year | +121.74% |
1 week
23.81
25.50
1 month
19.6126.54
Current year
7.3830.99
1 year
7.3839.60
3 years
7.38115.20
5 years
7.38190.00
10 years
7.38560.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Steven Tuch
DFI | Director of Finance/CFO | 56 | 22-12-07 |
Vanessa McDade
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | Feb. 26 |
Paul Sekhri
CEO | Chief Executive Officer | 66 | 22-07-31 |
Richard Nelson
BRD | Director/Board Member | 54 | 20-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 25.5 | +2.10% | 5,602 |
| 24-04-23 | 24.98 | +2.21% | 4,442 |
| 24-04-22 | 24.44 | +1.64% | 2,994 |
| 24-04-19 | 24.04 | -2.83% | 3,519 |
| 24-04-18 | 24.74 | +2.44% | 3,423 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +121.74% | 62.04M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.46% | 22.2B | |
| -16.53% | 21.23B | |
| -8.86% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- VTVT Stock
